CEO Change at dSPACE: Dr. Carsten Hoff Succeeds Martin Goetzeler
25.1.2023 17:54:00 EET | Business Wire | Press release
On April 17, 2023, Dr. Carsten Hoff (49) will become the new CEO of the dSPACE group succeeding Martin Goetzeler (60), who is leaving his post at his own request and for personal reasons. To ensure a smooth handover, Martin Goetzeler will continue to be available to the new CEO in an advisory capacity after April 17, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005072/en/
From left to right, dSPACE founder and shareholder Dr. Herbert Hanselmann, Dr. Carsten Hoff and Martin Goetzeler. (Photo: Business Wire)
Dr. Carsten Hoff is a highly experienced manager, who is ideally suited to the tasks ahead at dSPACE. He comes from a research and development-centric background with a degree in electrical engineering and a doctorate in computer science. He has international management experience and is familiar with dSPACE and the company's products.
Dr. Carsten Hoff is currently Managing Director of CLAAS E-Systems. Prior to that, he worked in various management positions at the automotive supplier HELLA. He will use his extensive experience from previous positions to provide strategic impetus for dSPACE and to continue to drive forward the new topics of software-based simulation and validation.
"I am very pleased to be joining the dSPACE company. I am very impressed by the company's development and dSPACE's role in the automotive industry. The values that the family-owned company dSPACE stands for convinced me,” stated Dr. Carsten Hoff.
"Dr. Carsten Hoff, an internationally experienced and technically skilled manager who is very familiar with the current challenges in our target markets is taking the helm – I wish him a good start in the company and with our customers," said Dr. Herbert Hanselmann, founder and shareholder of dSPACE.
"Under Martin Goetzeler's successful leadership, dSPACE has sustainably strengthened its market position by setting a decisive course in terms of consistent portfolio expansion, globalization, and future-oriented structures. By continually expanding future investments and the team, he has succeeded in continuing the great growth rate at a high level of sales in challenging years," said Dr. Herbert Hanselmann, adding, "We regret but respect Martin Goetzeler's decision. I would like to expressly thank him for his important contribution, his extraordinary commitment, and the close cooperation based on trust."
"It has been an exciting five years. The excellent and close cooperation with the entire dSPACE team, our customers and partners, and the shareholder family was the key to success and motivation at all times. I would like to thank everyone very much for this," said Martin Goetzeler. "After a fulfilling professional career, I would like to devote more time to my personal and family tasks and interests in the future. I wish my successor and all dSPACE employees the necessary skills, much success, and all the best for the future," said Goetzeler.
Martin Goetzeler has led the dSPACE company since March 1, 2018. Portfolio expansions in virtual and real simulation and validation to cover market and customer requirements in a timely manner, especially in automated and autonomous driving and in the software-defined vehicle were important milestones during this time. In addition to the great importance of software-in-the-loop simulation in this process, technologies such as AI and cloud are now also being used in the products. At the same time, he systematically built up structures and processes to sustainably secure the strong global growth.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 2,200 employees worldwide, dSPACE is headquartered in Paderborn, Germany, has three project centers in Germany, and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, Croatia, and South Korea.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005072/en/
Contact information
dSPACE GmbH
Bernd Schäfers-Maiwald
Vice President Corporate Communications
Tel: +49 5251 1638-714
E-Mail: bschaefers-maiwald@dspace.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom